Comparative effectiveness research for prostate cancer radiation therapy: Current status and future directions

Future Oncology

Volumn 8, Issue 1, 2012, Pages 37-54

  Shen, Xinglei ^a   Zaorsky, Nicholas G ^a   Mishra, Mark V ^a   Foley, Kathleen A ^b   Hyslop, Terry ^a   Hegarty, Sarah ^a   Pizzi, Laura T ^c   Dicker, Adam P ^a   Showalter, Timothy N ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMSON REUTERS   (United Kingdom)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

American Recovery and Reinvestment Act; comparative effectiveness research; cost effectiveness; patient centered outcomes research; prostate cancer; radiation therapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; COMPUTER ASSISTED RADIOTHERAPY; COST BENEFIT ANALYSIS; DECISION MAKING; GASTROINTESTINAL TOXICITY; MEDICAL INFORMATICS; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

COMPARATIVE EFFECTIVENESS RESEARCH; COST-BENEFIT ANALYSIS; DECISION MAKING; EVALUATION STUDIES AS TOPIC; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, COMPUTER-ASSISTED; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 83655182378     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.131     Document Type: Review

References (139)

1. IOM (Institute of Medicine). Initial National Priorities for Comparative Effectiveness Research. National Academies Press, Washington, DC, USA (2009).
2. Haynes B. Can it work? Does it work? Is it worth it? The testing of healthcare interventions is evolving. BMJ 319(7211), 652-653 (1999).
3. Sullivan P, Goldmann D. The promise of comparative effectiveness research. JAMA 305(4), 400-401 (2011).
4. Horn SD, Gassaway J, Pentz L, James R. Practice-based evidence for clinical practice improvement: an alternative study design for evidence-based medicine. Stud. Health Technol. Inform. 151, 446-460 (2010).
5. Thompson IM, Tangen CM, Paradelo J et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J. Urol. 181(3), 956-962 (2009).
6. Hoffman KE, Nguyen PL, Chen MH et al. Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trial. J. Urol. 185(1), 116-120 (2011).
7. Nielsen ME, Trock BJ, Walsh PC. Salvage or adjuvant radiation therapy: counseling patients on the benefits. J. Natl Compr. Canc. Netw. 8(2), 228-237 (2010).
8. Concato J, Lawler EV, Lew RA, Gaziano JM, Aslan M, Huang GD. Observational methods in comparative effectiveness research. Am. J. Med. 123(12A), E16-E23 (2010).
9. Epstein RS, Teagarden JR. Comparative effectiveness research and personalized medicine: catalyzing or colliding? Pharmacoeconomics 28(10), 905-913 (2010).
10. Epstein RS, Teagarden JR. Comparative effectiveness research and personalized medicine: catalyzing or colliding? Pharmacoeconomics 28(10), 905-913 (2010).
11. Marko NF, Weil RJ. The role of observational investigations in comparative effectiveness research. Value Health 13(8), 989-999 (2010).
12. Bekelman JE, Shah A, Hahn SM. Implications of comparative effectiveness research for radiation oncology. Practical Radiat. Oncol. 1(2), 72-80 (2011).
13. Schunemann HJ, Schunemann AH, Oxman AD et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 336(7653), 1106-1110 (2008). (Pubitemid 351731739)
14. Schunemann HJ, Oxman AD, Brozek J et al. GRADE: assessing the quality of evidence for diagnostic recommendations. Evid. Based Med. 13(6), 162-163 (2008).
15. Patel K. Health reform's tortuous route to the patient-centered outcomes research institute. Health Aff. 29(10), 1777-1782 (2010).
16. Bentzen SM, Parliament M, Deasy JO et al. Biomarkers and surrogate endpoints for normal-tissue effects of radiation therapy: the importance of dose-volume effects. Int. J. Radiat. Oncol. Biol. Phys. 73(Suppl. 3), S145-S150 (2010).
17. McClellan M, Benner J. Comparative effectiveness research: will it bend the health care cost curve and improve quality? Strat. Imp. Comparative Effectiveness Res. Meth. Data Infra. 7-14 (2009).
18. Konski A. Cost, quality, and value healthcare: a new paradigm. Oncology (Willston Park) 24(6), 542-543 (2010).
19. Perlroth DJ, Goldman DP, Garber AM. The potential impact of comparative effectiveness research on U.S. health care expenditures Demography 47(Suppl.), S173-S190 (2010).
20. 111th United States Congress. American Recovery and Reinvestment Act of 2009. 111-115 (2009).
21. 111th United States Congress. The Patient Protection and Affordable Care Act. 111-148 (2010).
22. Lauer MS, Collins FS. Using science to improve the nation's health system: NIH's commitment to comparative effectiveness research. JAMA 303(21), 2182-2183 (2010).
23. Vogel L. New US centre to boost comparative health research. CMAJ 182(10), E457-E458 (2010).
24. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 60(5), 277-300 (2010).
25. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J. Natl Cancer Inst. 103(2), 1-12 (2011).
26. Sanda MG, Dunn RL, Michalski JM et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N. Engl. J. Med. 358(12), 1250-1261 (2008). (Pubitemid 351439226)
27. Holmboe ES, Concato J. Treatment decisions for localized prostate cancer: asking men what's important. J. Gen. Intern. Med. 15, 694-701 (2000).
28. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J. Clin. Oncol. 28(7), 1117-1123 (2010).
29. Paulson DF, Lin GH, Hinshaw W, Stephani S. Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J. Urol. 128(3), 502-504 (1982). (Pubitemid 12037692)
30. Akakura K, Suzuki H, Ichikawa T et al. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months. Jpn J. Clin. Oncol. 36(12), 789-793 (2006). (Pubitemid 47090734)
31. Kupelian PA, Potters L, Khuntia D et al. Radical prostatectomy, external beam radiotherapy or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 58(1), 25-33 (2004). (Pubitemid 38010333)
32. D'amico A, Whittington R, Malkowicz S et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280, 969-974 (1998). (Pubitemid 28445094)
33. Lawton CA, Desilvio M, Lee WR et al. Results of a Phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (Radiation Therapy Oncology Group 98-05). Int. J. Radiat. Oncol. Biol. Phys. 67(1), 39-47 (2007). (Pubitemid 44959487)
34. Cooperberg MR, Vickers AJ, Broering JM, Carroll PR. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer 116(22), 5226-5234 (2010).
35. Madlung A, Simcock M, Ghadjar P. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer 117(15), 3532 (2011).
36. Froehner M. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer doi:10.1002/cncr.25819 (2010) (Epub ahead of print).
37. Liu L, Coker AL, Du XL, Cormier JN, Ford CE, Fang S. Long-term survival after radical prostatectomy compared with other treatments in older med with local/regional prostate cancer. J. Surg. Oncol. 97(7), 583-591 (2008). (Pubitemid 351794147)
38. Tward JD, Lee CM, Pappas LM, Szabo A, Gaffney DK, Shrieve DC. Survival of men with clinically localized prostate cancer treated with prostatectomy, brachytherapy, or no definitive treatment. Cancer 107(10), 2392-2400 (2006). (Pubitemid 44748522)
39. Lu-Yao GL, Potosky AL, Albertsen PC, Barry MJ, Wennberg JE. Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. J. Natl Cancer Inst. 88(3-4), 166-173 (1996). (Pubitemid 26065828)
40. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J. Clin. Oncol. 28(7), 1117-1123 (2010).
41. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J. Clin. Oncol. 22(11), 2141-2149 (2004).
42. Giordano SH, Kuo Y-F, Hortobagyi GN, Freeman J, Goodwin JS. Limits of observation data in determining outcomes from cancer therapy. Cancer 112, 2456-2466 (2008).
43. Hadley J, Yabroff KR, Barrett MJ, Penson DF, Saigal CS, Potosky AL. Comparative effectiveness of prostate cancer treatments: Evaluating statistical adjustments for confounding in observational data. J. Natl Cancer Inst. 102(23), 1780-1793 (2010).
44. Sanda MG, Dunn RL, Michalski J et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N. Engl. J. Med. 358(12), 1250-1261 (2008). (Pubitemid 351439226)
45. Potosky AL, Davis WW, Hoffman RM et al. Five-year outcomes after prosta tectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J. Natl Cancer Inst. 96(18), 1358-1367 (2004). (Pubitemid 39406169)
46. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann. Intern. Med. 148(6), 435-448 (2008). (Pubitemid 351665443)
47. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J. Clin. Oncol. 28(1), 126-131 (2010).
48. National Comprehensive Cancer Network: NCCN Clinical Practice Guizelines in Oncology: Prostate Cancer v.3.2010 (2010).
49. Hayes JH, Ollendorf DA, Pearson SD et al. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA 304(21), 2373-2380 (2010).
50. Thompson IM, Klotz L. Active surveillance for prostate cancer. JAMA 304(21), 2411-2412 (2010).
51. Davison BJ, Goldenberg SL. Patient acceptance of active surveillance as a treatment option for low-risk prostate cancer. BJU Int. 108(11), 1787-1793 (2011).
52. Nguyen PL, Gu X, Lipsitz SR et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J. Clin. Oncol. 291(12), 1517-1524 (2011).
53. Paganetti H, Kooy H. Proton radiation in the management of localized cancer. Expert Rev. Med. Devices 7(2), 275-285 (2010).
54. Kuban DA, Tucker SL, Dong L et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 70(1), 67-74 (2008). (Pubitemid 350251041)
55. Pollack A, Zagars GK, Smith LG et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J. Clin. Oncol. 18(23), 3904-3911 (2000).
56. Zietman AL, Desilvio ML, Slater JD et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294(10), 1233-1239 (2005). (Pubitemid 41352111)
57. Zietman AL. Correction: Inaccurate analysis and results in a study of radiation therapy in adenocarcinoma of the prostate. JAMA 299(8), 898-899 (2008). (Pubitemid 351397078)
58. Peeters ST, Heemsbergen WD, Koper PC et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized Phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J. Clin. Oncol. 24(13), 1990-1996 (2006). (Pubitemid 46622106)
59. Zelefsky MJ, Reuter VE, Fuks Z, Scardino PT, Shippy AM. Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. J. Urol. 179(4), 1368-1372 (2008).
60. Stone NN, Stock RG, Cesaretti JA, Unger P. Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes. Int. J. Radiat. Oncol. Biol. Phys. 76(2), 355-360 (2010).
61. Kuban D, Pollack A, Huang E et al. Hazards of dose escalation in prostate cancer radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 57(5), 1260-1268 (2003). (Pubitemid 37443963)
62. Vaarkamp J, Malde R, Dixit S, Hamilton CS. A comparison of conformal and intensity modulated treatment planning techniques for early prostate cancer. J. Med. Imaging Radiat. Oncol. 53(3), 310-317 (2009).
63. Tao Y, Lefkopoulos D, Ibrahima D et al. Comparison of dose contribution to normal pelvic tissues among conventional, conformal and intensity-modulated radiotherapy techniques in prostate cancer. Acta Oncol. 47(3), 442-450 (2008). (Pubitemid 351414931)
64. Bekelman JE, Mitra N, Efstathiou JA et al. Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 81(4), E325-E334 (2011).
65. Kim S, Shen S, Moore DF et al. Late gastrointestinal toxicities following radiation therapy for prostate cancer. Eur. Urol. 60(5), 908-916 (2011).
66. Virnig B, Warren JL, Cooper GS, Klabunde CN, Schussler N, Freeman J. Studying radiation therapy using SEER-Medicare-linked data. Med. Care 40(Suppl. 8), IV-49-54 (2002).
67. Potosky AL, Warren JL, Riedel ER, Klabunde CN, Earle CC, Begg CB. Measuring complications of cancer treatment using the SEER-Medicare data. Med. Care 40(Suppl. 8), 62-68 (2002).
68. Lips I, Dehnad H, Kruger AB et al. Health-related quality of life in patients with locally advanced prostate cancer after 76 Gy intensity-modulated radiotherapy vs. 70 Gy conformal radiotherapy in a prospective and longitudinal study. Int. J. Radiat. Oncol. Biol. Phys. 69(3), 656-661 (2007). (Pubitemid 47418401)
69. Cahlon O, Zelefsky MJ, Shippy A et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int. J. Radiat. Oncol. Biol. Phys. 71(2), 330-337 (2008).
70. Trofimov A, Nguyen PL, Coen JJ et al. Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison. Int. J. Radiat. Oncol. Biol. Phys. 69(2), 444-453 (2007). (Pubitemid 47380086)
71. Dearnaley DP, Sydes MR, Graham JD et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 8(6), 475-487 (2007). (Pubitemid 46805903)
72. Peeters STH, Heemsbergen WD, Van Putten WLJ et al. Acute and late complications after radiotherapy for prostate cancer: Results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int. J. Radiat. Oncol. Biol. Phys. 61(4), 1019-1034 (2005). (Pubitemid 40340897)
73. Storey MR, Pollack A, Zagars G, Smith L, Antolak J, Rosen I. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 48(3), 635-642 (2000).
74. Zietman AL, Bae K, Slater JD et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J. Clin. Oncol. 28(7), 1106-1111 (2010).
75. Mendenhall NP, Li Z, Hoppe BS et al. Early outcomes from three prospective trials of image-guided proton therapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. doi:10.1016/j.ijrobp.2010.09.024 (2010) (Epub ahead of print).
76. Slater JD, Rossi CJ Jr, Yonemoto LT et al. Proton therapy for prostate cancer: the initial Loma Linda University experience. Int. J. Radiat. Oncol. Biol. Phys. 59(2), 348-352 (2004). (Pubitemid 38622585)
77. Coen JJ, Bae K, Zietman AL et al. Acute and late toxicity after dose escalation to 82 GyE using conformal proton radiation for localized prostate cancer: initial report of American College of Radiology Phase II study 03-12. Int. J. Radiat. Oncol. Biol. Phys. 81(4), 1005-1009 (2010).
78. Kim S, Shen S, Moore DF et al. Late gastrointestinal toxicities following radiation therapy for prostate cancer. Eur. Urol. 60(5), 908-916 (2011).
79. Kraemer HC, Frank E. Evaluation of comparative treatment trials: assessing clinical benefits and risks for patients, rather than statistical effects on measures. JAMA 304(6), 683-684 (2010).
80. D'amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11), 969-974 (1998). (Pubitemid 28445094)
81. Zelefsky MJ, Yamada Y, Pei X et al. Comparison of tumor control and toxicity outcomes of high-dose intensity-modulated radiotherapy and brachytherapy for patients with favorable risk prostate cancer. Urology 77(4), 986-990 (2011).
82. Stone NN, Potters L, Davis BJ et al. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 73(2), 341-346 (2009).
83. Jabbari S, Weinberg VK, Shinohara K et al. Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost. Int. J. Radiat. Oncol. Biol. Phys. 76(1), 36-42 (2010).
84. Coen JJ, Zietman AL, Rossi CJ et al. Comparison of high-dose proton radiotherapy and brachytherapy in localized prostate cancer: a case-matched analysis. Int. J. Radiat. Oncol. Biol. Phys. doi:10.1016/j. ijrobp.2011.01.039 (2011) (Epub ahead of print).
85. Sylvester JE, Grimm PD, Blasko JC et al. 15 year biochemical relapse free survival in clinical stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int. J. Radiat. Oncol. Biol. Phys. 67(1), 57-64 (2007). (Pubitemid 44959493)
86. Liu HW, Malkoske K, Sasaki D et al. The dosimetric quality of brachytherapy implants in patients with small prostate volume depends on the experience of the brachytherapy team. Brachytherapy 9(3), 202-207 (2010).
87. Chen AB, D'amico AV, Neville BA, Steyerberg EW, Earle CC. Provider case volume and outcomes following prostate brachytherapy. J. Urol. 181(1), 113-118 (2009).
88. Shen X, Keith SW, Mishra MV, Dicker AP, Showalter TN. Prostate seed implantation alone or with external beam radiation therapy reduces cause-specific mortality compared with external beam radiation therapy for definitive treatment of localized intermediate to high risk prostate cancer: a population based analysis. Presented at: American Brachytherapy Soceity Annual Meeting. San Diego, CA, USA, 14-16 April 2011.
89. Shen X, Keith SW, Mishra MV, Dicker AP, Showalter TN. The impact of brachytherapy on prostate cancer-specific mortality for definitive radiation therapy of high-grade prostate cancer: a population-based analysis. Int. J. Radiation Oncol. Biol. Phys. (In Press) (2011).
90. Kilbridge KL. Quality-adjusted life-years, comparative effectiveness in cancer care, and measuring outcomes in the underserved. Oncology (Willston Park) 24(6), 530-536 (2010).
91. Konski A, Watkins-Bruner D, Feigenberg S et al. Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk porostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 66(2), 408-415 (2006). (Pubitemid 44332736)
92. Konski A, Watkins-Bruner D, Feigenberg S et al. Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 66(2), 408-415 (2006). (Pubitemid 44332736)
93. Steinberg ML, Konski A. Proton beam therapy and the convoluted pathway to incorporating emerging technology into routine medical care in the United States. Cancer J. 15(4), 333-338 (2009).
94. Elliott SP, Wilt TJ, Kuntz KM. Projecting the clinical benefits of adjuvant radiotherapy versus observation and selective salvage radiotherapy after radical prostatectomy: a decision analysis. Prostate Cancer Prostatic Dis. 14(3), 270-277 (2011).
95. Luce BR, Kramer JM, Goodman SN et al. Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change. Ann. Intern. Med. 151(3), 206-209 (2009).
96. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 290(12), 1624-1632 (2003). (Pubitemid 37430387)
97. Zwarenstein M, Treweek S, Gagnier JJ et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ 337, a2390 (2008).
98. Griffin SJ, Borch-Johnsen K, Davies MJ et al. Effect of early intensive multifactorial therapy on 5 year cardiovascular outcomes in individuals with Type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 378(9786), 156-167 (2011).
99. Callaghan P, Khalil E, Morres I, Carter T. Pragmatic randomised controlled trial of preferred intensity exercise in women living with depression. BMC Public Health. 11, 465 (2011).
100. Chow SC, Chang M. Adaptive design methods in clinical trials - a review. Orphanet. J. Rare Dis. 3, 11 (2008).
101. Thompson IM Jr, Tangen CM, Paradelo J et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296(19), 2329-2335 (2006). (Pubitemid 44749360)
102. Wiegel T, Bottke D, Steiner U et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J. Clin. Oncol. 27(18), 2924-2930 (2009).
103. Bolla M, Van Poppel H, Collette L, Van Cangh P, Vekemans K, Pozzo LD. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366, 572-578 (2005). (Pubitemid 41140332)
104. Ghia AJ, Shrieve DC, Tward JD. Adjuvant radiotherapy use and patterns of care analysis for margin-positive prostate adenocarcinoma with extracapsular extension: Postprostatectomy adjuvant radiotherapy: a SEER analysis. Urology 76(5), 1169-1174 (2010).
105. Hoffman KE, Nguyen PL, Chen MH et al. Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trial. J. Urol. 185(1), 116-120 (2011).
106. Schreiber D, Rineer J, Yu JB et al. Analysis of pathologic extent of disease for clinically localized prostate cancer after radical prostatectomy and subsequent use of adjuvant radiation in a national cohort. Cancer 116(24), 5757-5766 (2010).
107. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat. Med. 17, 2265-2281 (1998).
108. Seeger JD, Kurth T, Walker AM. Use of propensity score technique to account for exposure-related covariates: an example and lesson. Med. Care 45(10 Suppl. 2), S143-S148 (2007).
109. Rassen JA, Schneeweiss S, Glynn RJ, Mittleman MA, Brookhart MA. Instrumental variable analysis for estimation of treatment effects with dichotomous outcomes. Am. J. Epidemiol. 169(3), 273-284 (2009).
110. Brookhart MA, Schneeweiss S. Preference-based instrumental variable methods for the estimation of treatment effects: assessing validity and interpreting results. Int. J. Biostat. 3(1), 14 (2007).
111. Basu A. Individualization at the heart of comparative effectiveness research: the time for i-CER has come. Med. Decis. Making 29(6), NP9-NP11 (2009).
112. Lohr KN. Comparative effectiveness research methods: symposium overview and summary. Med. Care 48(6 Suppl. 1), S3-S6 (2010).
113. Yarbro JW, Page DL, Fielding LP, Partridge EE, Murphy GP. American Joint Committee on Cancer prognostic factors consensus conference. Cancer 86(11), 2436-2446 (1999). (Pubitemid 30010388)
114. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann. Surg. Oncol. 17(6), 1471-1474 (2010).
115. Bolla M, Van Tienhoven G, Warde P et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10 year results of an EORTC randomised study. Lancet Oncol. 11(11), 1066-1073 (2010).
116. Pilepich MV, Winter K, Lawton CA et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of Phase III RTOG 85-31. Int. J. Radiat. Oncol. Biol. Phys. 61(5), 1285-1290 (2005). (Pubitemid 40470408)
117. Lawton CA, Desilvio M, Roach M 3rd et al. An update of the Phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int. J. Radiat. Oncol. Biol. Phys. 69(3), 646-655 (2007). (Pubitemid 47418390)
118. Horwitz EM, Bae K, Hanks GE et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a Phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J. Clin. Oncol. 26(15), 2497-2504 (2008).
119. Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J. Urol. 170(6 Pt 2), S21-S25; discussion S26-S27 (2003).
120. Hayes SB, Pollack A. Parameters for treatment decisions for salvage radiation therapy. J. Clin. Oncol. 23(32), 8204-8211 (2005). (Pubitemid 46211556)
121. San Francisco IF, Regan MM, Olumi AF, DeWolf WC. Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radiacal prostatectomy than prostate specfic antigen. J. Urol. 171(4), 1492-1499 (2004). (Pubitemid 38365404)
122. Roach M 3rd, Marquez C, Yuo HS et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 28(1), 33-37 (1994). (Pubitemid 24012852)
123. Nguyen PL, Chen MH, Hoffman KE, Katz MS, D'amico AV. Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era. Int. J. Radiat. Oncol. Biol. Phys. 74(1), 104-109 (2009).
124. Pencina MJ, D'agostino RB Sr, D'agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat. Med. 27(2), 157-172; discussion 207-212 (2008).
125. Buyyounouski MK, Li T, Al-Saleem T, Horwitz EM, Pollack A. Predicting local persistence of prostate cancer using percentage of adenocarcinoma in pretreatment biopsy tissue. Proceeding of the 2008 Genitourinary Cancers Symposium. San Francisco, CA, USA, 14-16 February 2008.
126. Comperat E, Roupret M, Drouin SJ et al. Tissue expression of IL16 in prostate cancer and its association with recurrence after radical prostatectomy. Prostate 70(15), 1622-1627 (2010).
127. Khor LY, Moughan J, Al-Saleem T et al. Bcl 2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02. Clin. Cancer Res. 13(12), 3585-3590 (2007). (Pubitemid 46955119)
128. Zhou JR, Yu L, Zerbini LF, Libermann TA, Blackburn GL. Progression to androgen-independent LNCaP human prostate tumors: cellular and molecular alterations. Int. J. Cancer 110(6), 800-806 (2004). (Pubitemid 38758504)
129. Khor LY, Bae K, Pollack A et al. COX 2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncol. 8(10), 912-920 (2007). (Pubitemid 47495777)
130. Li R, Wheeler T, Dai H, Frolov A, Thompson T, Ayala G. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. Am. J. Surg. Pathol. 28(7), 928-934 (2004). (Pubitemid 38856850)
131. Hu YC, Yeh S, Yeh SD et al. Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer. J. Biol. Chem. 279(32), 33438-33446 (2004). (Pubitemid 39062993)
132. Li X, Strauss L, Makela S et al. Multiple structural and functional abnormalities in the p450 aromatase expressing transgenic male mice are ameliorated by a p450 aromatase inhibitor. Am. J. Pathol. 164(3), 1039-1048 (2004). (Pubitemid 38235485)
133. Culyer AJ. Perspective and desire in comparative effectiveness research: the relative unimportance of mere preferences, the central importance of context. Pharmacoeconomics 28(10), 889-897 (2010).
134. Sommers BD, Beard CJ, D'amico AV et al. Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer. Cancer 110, 2210-2217 (2007). (Pubitemid 350100742)
135. D'avolio LW, Farwell WR, Fiore LD. Comparative effectiveness research and medical informatics. Am. J. Med. 123(12A), e32-e37 (2010).
136. Michalski JM, Gay H, Jackson A, Tucker SL, Deasy JO. Radiation dose-volume effects in radiation-induced rectal injury. Int. J. Radiat. Oncol. Biol. Phys. 76(Suppl. 3), S123-S129 (2010).
137. Schreiber D, Rineer J, Yu JB et al. Analysis of pathologic extent of disease for clinically localized prostate cancer after radical prostatectomy and subsequent use of adjuvant radiation in a national cohort. Cancer. 116(24), 5757-5766 (2010).
138. Showalter TN, Ohri N, Teti KG et al. Physician beliefs and practices for adjuvant and salvage radiation therapy after prostatectomy. Int. J. Radiat. Oncol. Biol. Phys. doi:10.1016/j.ijrobp.2011.04.003 (2011) (Epub ahead of print).
139. Guyatt GH, Oxman AD, Aki EA et al. GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables. J. Clin. Epidemol. 64(4), 383-394 (2011).